Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + gemcitabine + paclitaxel

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination chemotherapy regimen consisting of four anticancer drugs: cyclophosphamide, doxorubicin (Adriamycin), gemcitabine (Gemzar), and paclitaxel (Taxol). This specific four-drug combination has been studied in breast cancer treatment. The combination works through multiple mechanisms: doxorubicin damages DNA at any point in the cell cycle, cyclophosphamide damages DNA during the resting phase, gemcitabine is a nucleoside analog that inhibits DNA synthesis, and paclitaxel stabilizes microtubules and blocks cells in the G2/M mitotic phase.

Targets

TOP2A (DNA topoisomerase II)MicrotubuleDNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + gemcitabine + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + gemcitabine + paclitaxel.

Explore the full profile